Prosecution Insights
Last updated: April 19, 2026
Application No. 18/649,168

DISTRIBUTED MULTI-CAMERA REAL-TIME TUMOR POSITIONING AND TRACKING METHOD BASED ON VISUAL POSITION-AWARE MARK AND TRACKING SYSTEM THEREOF

Non-Final OA §112
Filed
Apr 29, 2024
Examiner
TOOHEY, RICHARD ORLANDO
Art Unit
2884
Tech Center
2800 — Semiconductors & Electrical Systems
Assignee
Fujian Medical University Union Hospital
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
2y 6m
To Grant
93%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allow Rate
44 granted / 54 resolved
+13.5% vs TC avg
Moderate +12% lift
Without
With
+11.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
24 currently pending
Career history
78
Total Applications
across all art units

Statute-Specific Performance

§101
4.4%
-35.6% vs TC avg
§103
44.5%
+4.5% vs TC avg
§102
24.5%
-15.5% vs TC avg
§112
22.3%
-17.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 54 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Specification The disclosure is objected to because of the following informalities: The specification refers to both a “Hella code” and a “HELAC code.” The corresponding Chinese application translates the same structure to a “Haila code.” It is interpreted that at least one, if not all, of these unrecognized terms are a translation error. Appropriate correction is required. Claim Objections Claims 1-10 are objected to because of the following informalities: The claims make reference to a “Hella code.” Hella code is not an art recognized term. Additionally, the specification refers to both a “Hella code” and a “HELAC code.” The corresponding Chinese application translates the same structure to a “Haila code.” It is interpreted that at least one, if not all, of these unrecognized terms are a translation error. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. In order to determine compliance with the enablement requirement of 35 U.S.C. 112(a), the Federal Circuit developed a framework of factors in In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988), referred to as the Wands factors to assess whether any necessary experimentation required by the specification is "reasonable" or is "undue." Consistent with Amgen Inc. et al. v. Sanofi et al., 598 U.S. 594, 2023 USPQ2d 602 (2023), the Wands factors continue to provide a framework for assessing enablement in a utility application or patent, regardless of technology area. See Guidelines for Assessing Enablement in Utility Applications and Patents in View of the Supreme Court Decision in Amgen Inc. et al. v. Sanofi et al., 89 FR 1563 (January 10, 2024). These factors include, but are not limited to: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) Regarding claim 1 the factors weigh as follows: The breadth of the claim is unable to be determined as the key structure of the claims are a “Hella code” which is not an art recognized term and is not defined by the specification. The nature of the invention is in some way locating a position and tracking the position of a tumor. The method is unable to be determined as the key structure of the claims are a “Hella code” which is not an art recognized term and is not defined by the specification. The state of the prior art is unable to be determined as the key structure of the claims are a “Hella code” which is not an art recognized term and is not defined by the specification. The level of one of ordinary skill would be unable to determine the structure of a “Hella code” because it is not an art recognized term and is not defined in the specification. The level of predictability in the art is unable to be determined as the key structure of the claims are a “Hella code” which is not an art recognized term and is not defined by the specification The inventor fails to define a “Hella code.” The existence of working examples is unable to be determined as the key structure of the claims are a “Hella code” which is not an art recognized term and is not defined by the specification The quantity of experimentation is unable to be determined as the key structure of the claims are a “Hella code” which is not an art recognized term and is not defined by the specification. For these reasons, claim 1 fails to comply with the enablement requirement. Claims 2-10 are dependent on claim 1 and are rejected for the same reason. Claims 1-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the claim limitation “Hella code” is indefinite insofar as the examiner is unclear about the structure of “Hella Code” and it is impossible to determine the intending scope of the structure of “Hella Code” in claim 1. Hella code is not an art recognized term. Additionally, the specification refers to both a “Hella code” and a “HELAC code.” The corresponding Chinese application translates the same structure to a “Haila code.” It is interpreted that at least one, if not all, of these unrecognized terms are a translation error and it is impossible to determine the structure of the “Hella code” Also, dependent Claims 2-10 are rejected by virtue of its dependency. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Ferte teaches a method for feature extraction and evaluation for monitoring and identifying tumors (abstract, pg. 10-11), comprising: dividing a image into a plurality of voxels, extract a variety of features from said image, encoding said features into a scoring code, comparing said cade with a reference value, and deriving the presence, density, or evolution of a tumor (pg. 10-11). Yan teaches a self-recognizing method of image segmentation in medical imaging (abstract, pg. 2). Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard Toohey whose telephone number is (703)756-5818. The examiner can normally be reached Mon-Fri: 7:30am – 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, the applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Uzma Alam can be reached on (571)272-2995. The fax number for the organization where this application or processing is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RICHARD O TOOHEY/Examiner, Art Unit 2884 /EDWIN C GUNBERG/Primary Examiner, Art Unit 2884
Read full office action

Prosecution Timeline

Apr 29, 2024
Application Filed
Jan 27, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12601637
VACUUM HEALTH DETECTION FOR IMAGING SYSTEMS AND METHODS
2y 5m to grant Granted Apr 14, 2026
Patent 12596200
HYBRID NEUROMORPHIC X-RAY IMAGING SYSTEM AND METHOD OF USING THE SAME
2y 5m to grant Granted Apr 07, 2026
Patent 12588882
ENERGY SUBTRACTION PROCESSING APPARATUS, ENERGY SUBTRACTION PROCESSING METHOD, RADIATION IMAGING SYSTEM, AND NON-TRANSITORY COMPUTER-READABLE STORAGE MEDIUM
2y 5m to grant Granted Mar 31, 2026
Patent 12588879
RADIATION DETECTION APPARATUS, SENSOR MODULE, AND CT APPARATUS
2y 5m to grant Granted Mar 31, 2026
Patent 12580064
METHOD FOR DETERMINING A TREATMENT PLAN INCLUDING A DOSE DISTRIBUTION
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
93%
With Interview (+11.8%)
2y 6m
Median Time to Grant
Low
PTA Risk
Based on 54 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month